Specifically, fisetin was shown to have anti-cancer activity by modulating PI3K/AKT/mTOR pathway in various types of cancer (Farooqi et al., 2021; Rychahou et al., 2006; Xiao et al., 2021; Zhang & Jia, 2016). This evidence concerns the gene AKT1 and cancer.